Concepts (267)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Maternal Mortality | 2 | 2019 | 461 | 1.09 | Why? |
| Terminal Care | 5 | 2019 | 928 | 1.03 | Why? |
| Hemorrhagic Fever, Ebola | 6 | 2019 | 1475 | 0.73 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 9 | 2020 | 8843 | 0.65 | Why? |
| Critical Care | 11 | 2021 | 14081 | 0.57 | Why? |
| Risk Adjustment | 2 | 2017 | 730 | 0.53 | Why? |
| Bacteremia | 3 | 2019 | 1372 | 0.53 | Why? |
| Critical Illness | 14 | 2021 | 17281 | 0.53 | Why? |
| Maternal Health | 1 | 2017 | 331 | 0.50 | Why? |
| Morbidity | 1 | 2019 | 1426 | 0.49 | Why? |
| Interferon beta-1b | 3 | 2020 | 274 | 0.49 | Why? |
| Abortion, Induced | 1 | 2019 | 437 | 0.48 | Why? |
| Ventilators, Mechanical | 2 | 2021 | 2193 | 0.45 | Why? |
| Burns | 4 | 2017 | 466 | 0.42 | Why? |
| Ontario | 9 | 2019 | 1966 | 0.41 | Why? |
| Plasma Exchange | 1 | 2016 | 763 | 0.38 | Why? |
| Emigrants and Immigrants | 1 | 2017 | 888 | 0.37 | Why? |
| Physicians | 2 | 2019 | 4214 | 0.36 | Why? |
| Ritonavir | 5 | 2021 | 4212 | 0.36 | Why? |
| Pregnancy Complications | 1 | 2019 | 1388 | 0.35 | Why? |
| Respiratory Tract Diseases | 1 | 2016 | 1061 | 0.34 | Why? |
| Ebolavirus | 4 | 2019 | 834 | 0.34 | Why? |
| Poisson Distribution | 2 | 2019 | 348 | 0.34 | Why? |
| Randomized Controlled Trials as Topic | 8 | 2021 | 10649 | 0.33 | Why? |
| Lopinavir | 5 | 2021 | 4308 | 0.31 | Why? |
| Health Care Rationing | 1 | 2020 | 2558 | 0.30 | Why? |
| Antiviral Agents | 10 | 2021 | 41703 | 0.30 | Why? |
| Advance Care Planning | 1 | 2011 | 426 | 0.29 | Why? |
| Post-Exposure Prophylaxis | 2 | 2021 | 472 | 0.28 | Why? |
| Communication Barriers | 2 | 2018 | 246 | 0.28 | Why? |
| Saudi Arabia | 8 | 2020 | 4423 | 0.27 | Why? |
| Heparin | 3 | 2021 | 2600 | 0.26 | Why? |
| Coronavirus Infections | 19 | 2020 | 253789 | 0.24 | Why? |
| Patient Care Planning | 2 | 2018 | 582 | 0.24 | Why? |
| Drug Combinations | 6 | 2021 | 3852 | 0.22 | Why? |
| Triage | 1 | 2020 | 7151 | 0.22 | Why? |
| Burn Units | 3 | 2017 | 179 | 0.21 | Why? |
| Canada | 8 | 2021 | 6018 | 0.21 | Why? |
| Intensive Care Units | 12 | 2021 | 29594 | 0.20 | Why? |
| Amodiaquine | 1 | 2019 | 57 | 0.20 | Why? |
| Health Care Costs | 2 | 2018 | 1007 | 0.19 | Why? |
| Peripartum Period | 1 | 2019 | 89 | 0.19 | Why? |
| Attitude of Health Personnel | 2 | 2018 | 4741 | 0.19 | Why? |
| Urinary Bladder, Overactive | 1 | 2018 | 40 | 0.19 | Why? |
| Hospitalization | 11 | 2021 | 54280 | 0.18 | Why? |
| Maternal Age | 1 | 2019 | 244 | 0.18 | Why? |
| Dialysis | 1 | 2017 | 45 | 0.18 | Why? |
| Humans | 62 | 2021 | 930598 | 0.17 | Why? |
| Smoke Inhalation Injury | 1 | 2017 | 22 | 0.17 | Why? |
| Databases, Factual | 5 | 2019 | 6248 | 0.17 | Why? |
| Vital Statistics | 1 | 2017 | 89 | 0.17 | Why? |
| Artemisinins | 1 | 2019 | 238 | 0.16 | Why? |
| Anti-Bacterial Agents | 4 | 2019 | 10083 | 0.16 | Why? |
| Drug Therapy | 1 | 2019 | 280 | 0.16 | Why? |
| Decision Making | 1 | 2011 | 3132 | 0.16 | Why? |
| Ebola Vaccines | 1 | 2017 | 126 | 0.16 | Why? |
| Absenteeism | 1 | 2018 | 287 | 0.16 | Why? |
| Therapeutic Human Experimentation | 1 | 2016 | 39 | 0.15 | Why? |
| Sex Distribution | 3 | 2017 | 2083 | 0.15 | Why? |
| Macrolides | 1 | 2019 | 369 | 0.15 | Why? |
| Biomedical Research | 1 | 2016 | 5270 | 0.15 | Why? |
| Noninvasive Ventilation | 2 | 2019 | 2329 | 0.14 | Why? |
| Cataract Extraction | 1 | 2018 | 201 | 0.14 | Why? |
| Influenza A Virus, H1N1 Subtype | 3 | 2018 | 2984 | 0.14 | Why? |
| Respiration, Artificial | 5 | 2021 | 22116 | 0.14 | Why? |
| Enteral Nutrition | 1 | 2017 | 320 | 0.14 | Why? |
| Thrombosis | 3 | 2021 | 7504 | 0.14 | Why? |
| Sample Size | 1 | 2016 | 518 | 0.14 | Why? |
| Patient Acceptance of Health Care | 3 | 2017 | 5002 | 0.13 | Why? |
| Organ Dysfunction Scores | 1 | 2020 | 1475 | 0.13 | Why? |
| International Classification of Diseases | 1 | 2017 | 265 | 0.13 | Why? |
| Body Fluids | 1 | 2018 | 451 | 0.13 | Why? |
| Eye | 1 | 2018 | 374 | 0.13 | Why? |
| Research | 2 | 2017 | 2115 | 0.13 | Why? |
| Surveys and Questionnaires | 4 | 2019 | 43792 | 0.13 | Why? |
| Adrenal Cortex Hormones | 3 | 2020 | 6537 | 0.13 | Why? |
| Drug Utilization | 1 | 2018 | 619 | 0.13 | Why? |
| Female | 31 | 2021 | 380317 | 0.13 | Why? |
| Receptors, Interleukin-6 | 1 | 2021 | 1383 | 0.12 | Why? |
| Delivery of Health Care | 1 | 2019 | 15909 | 0.12 | Why? |
| Insurance, Health | 1 | 2018 | 634 | 0.12 | Why? |
| New York | 1 | 2020 | 2488 | 0.12 | Why? |
| Postpartum Period | 1 | 2019 | 936 | 0.12 | Why? |
| Observational Studies as Topic | 2 | 2018 | 1887 | 0.12 | Why? |
| Disease Transmission, Infectious | 3 | 2021 | 9044 | 0.12 | Why? |
| Middle East | 1 | 2017 | 1418 | 0.12 | Why? |
| Regression Analysis | 1 | 2019 | 2484 | 0.11 | Why? |
| Anticoagulants | 3 | 2021 | 9563 | 0.11 | Why? |
| Oncologists | 1 | 2018 | 877 | 0.11 | Why? |
| Patient Transfer | 1 | 2018 | 898 | 0.11 | Why? |
| Subthalamic Nucleus | 1 | 2010 | 36 | 0.11 | Why? |
| Male | 29 | 2021 | 367725 | 0.11 | Why? |
| DNA, Viral | 1 | 2021 | 2521 | 0.10 | Why? |
| Asia | 1 | 2017 | 2399 | 0.10 | Why? |
| Feasibility Studies | 2 | 2018 | 3467 | 0.10 | Why? |
| Hydrocortisone | 1 | 2020 | 1790 | 0.10 | Why? |
| Income | 1 | 2019 | 1564 | 0.10 | Why? |
| Palliative Care | 3 | 2019 | 2665 | 0.10 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.10 | Why? |
| Influenza, Human | 3 | 2018 | 10779 | 0.09 | Why? |
| Hospitals, Teaching | 1 | 2017 | 1609 | 0.09 | Why? |
| Prenatal Care | 1 | 2019 | 1314 | 0.09 | Why? |
| Nurse-Patient Relations | 1 | 2011 | 168 | 0.09 | Why? |
| Aged | 17 | 2021 | 215776 | 0.09 | Why? |
| Analgesics, Opioid | 1 | 2018 | 1070 | 0.09 | Why? |
| Adult | 22 | 2021 | 244371 | 0.09 | Why? |
| Middle Aged | 22 | 2021 | 270681 | 0.09 | Why? |
| Respiratory Insufficiency | 2 | 2021 | 7301 | 0.09 | Why? |
| Evidence-Based Medicine | 2 | 2020 | 3228 | 0.09 | Why? |
| Pyrazines | 1 | 2019 | 1783 | 0.09 | Why? |
| Continuity of Patient Care | 1 | 2018 | 1574 | 0.09 | Why? |
| Deep Brain Stimulation | 1 | 2010 | 203 | 0.09 | Why? |
| Sierra Leone | 2 | 2018 | 267 | 0.09 | Why? |
| Europe | 2 | 2017 | 12702 | 0.09 | Why? |
| Amides | 1 | 2019 | 1864 | 0.09 | Why? |
| Ambulatory Care Facilities | 1 | 2019 | 2063 | 0.09 | Why? |
| Cohort Studies | 4 | 2019 | 36005 | 0.09 | Why? |
| Viruses | 1 | 2021 | 2238 | 0.08 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.08 | Why? |
| Attitude to Death | 1 | 2011 | 307 | 0.08 | Why? |
| Family | 2 | 2018 | 2909 | 0.08 | Why? |
| Time Factors | 7 | 2020 | 31397 | 0.08 | Why? |
| Occupational Stress | 1 | 2021 | 2044 | 0.08 | Why? |
| Severity of Illness Index | 5 | 2021 | 48226 | 0.08 | Why? |
| Treatment Outcome | 11 | 2021 | 51732 | 0.08 | Why? |
| Pandemics | 11 | 2021 | 389249 | 0.08 | Why? |
| North America | 1 | 2011 | 1400 | 0.08 | Why? |
| Anti-Infective Agents | 1 | 2018 | 1766 | 0.08 | Why? |
| Influenza A virus | 1 | 2018 | 2234 | 0.08 | Why? |
| Pregnancy | 2 | 2019 | 23879 | 0.08 | Why? |
| Survivors | 1 | 2018 | 2619 | 0.07 | Why? |
| Physician-Patient Relations | 2 | 2018 | 1266 | 0.07 | Why? |
| Community-Acquired Infections | 1 | 2018 | 2328 | 0.07 | Why? |
| Patient Satisfaction | 1 | 2018 | 2517 | 0.07 | Why? |
| Cross Infection | 2 | 2018 | 8675 | 0.07 | Why? |
| Multiple Organ Failure | 1 | 2014 | 1724 | 0.07 | Why? |
| Tracheostomy | 1 | 2017 | 1963 | 0.07 | Why? |
| Treatment Failure | 2 | 2021 | 2106 | 0.07 | Why? |
| Double-Blind Method | 3 | 2020 | 5988 | 0.07 | Why? |
| Cause of Death | 1 | 2017 | 4823 | 0.06 | Why? |
| Virus Diseases | 1 | 2021 | 3779 | 0.06 | Why? |
| Case-Control Studies | 2 | 2019 | 17671 | 0.06 | Why? |
| Health Status | 1 | 2016 | 3259 | 0.06 | Why? |
| Decision Support Techniques | 1 | 2010 | 903 | 0.06 | Why? |
| Adolescent | 8 | 2020 | 86841 | 0.06 | Why? |
| Communicable Diseases, Emerging | 1 | 2017 | 2523 | 0.06 | Why? |
| Young Adult | 8 | 2020 | 93724 | 0.06 | Why? |
| Cardiology | 1 | 2017 | 2873 | 0.06 | Why? |
| Influenza Vaccines | 1 | 2018 | 2941 | 0.06 | Why? |
| Retrospective Studies | 8 | 2020 | 105322 | 0.06 | Why? |
| Disease Models, Animal | 2 | 2017 | 10998 | 0.06 | Why? |
| Multicenter Studies as Topic | 2 | 2020 | 2437 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.06 | Why? |
| Practice Guidelines as Topic | 3 | 2020 | 15421 | 0.06 | Why? |
| Dose-Response Relationship, Drug | 2 | 2021 | 3776 | 0.05 | Why? |
| Aged, 80 and over | 4 | 2019 | 88759 | 0.05 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.05 | Why? |
| Needs Assessment | 1 | 2011 | 2352 | 0.05 | Why? |
| Ambulatory Care | 1 | 2018 | 4947 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2019 | 4927 | 0.05 | Why? |
| Antibodies, Monoclonal | 1 | 2019 | 8041 | 0.05 | Why? |
| United States | 3 | 2018 | 46150 | 0.05 | Why? |
| Emergency Service, Hospital | 3 | 2019 | 14232 | 0.05 | Why? |
| Influenza A Virus, H1N2 Subtype | 1 | 2018 | 19 | 0.05 | Why? |
| Insurance, Disability | 1 | 2018 | 11 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 9335 | 0.05 | Why? |
| Hemorrhage | 2 | 2021 | 3013 | 0.05 | Why? |
| Injections, Subcutaneous | 1 | 2020 | 647 | 0.05 | Why? |
| Animals | 3 | 2017 | 78931 | 0.05 | Why? |
| Monitoring, Physiologic | 2 | 2021 | 1956 | 0.04 | Why? |
| Burns, Electric | 1 | 2017 | 2 | 0.04 | Why? |
| Parkinson Disease | 1 | 2010 | 1414 | 0.04 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2018 | 13720 | 0.04 | Why? |
| Age Distribution | 2 | 2017 | 3567 | 0.04 | Why? |
| Body Surface Area | 1 | 2017 | 50 | 0.04 | Why? |
| Early Termination of Clinical Trials | 1 | 2020 | 1256 | 0.04 | Why? |
| Statistics, Nonparametric | 1 | 2020 | 1008 | 0.04 | Why? |
| Prospective Studies | 2 | 2019 | 43301 | 0.04 | Why? |
| Registries | 1 | 2017 | 12327 | 0.04 | Why? |
| Time | 1 | 2019 | 631 | 0.04 | Why? |
| Africa, Western | 1 | 2017 | 363 | 0.04 | Why? |
| Organizational Policy | 1 | 2021 | 694 | 0.04 | Why? |
| Heart Failure | 1 | 2017 | 6638 | 0.04 | Why? |
| Intubation | 1 | 2018 | 437 | 0.04 | Why? |
| Survival Analysis | 2 | 2021 | 7592 | 0.04 | Why? |
| Pilot Projects | 2 | 2018 | 5182 | 0.04 | Why? |
| Italy | 1 | 2020 | 38444 | 0.04 | Why? |
| Data Interpretation, Statistical | 1 | 2020 | 657 | 0.04 | Why? |
| Drug Therapy, Combination | 2 | 2020 | 7268 | 0.04 | Why? |
| Child | 3 | 2019 | 70012 | 0.04 | Why? |
| Cataract | 1 | 2018 | 186 | 0.04 | Why? |
| Mental Disorders | 1 | 2017 | 6742 | 0.03 | Why? |
| Visitors to Patients | 1 | 2021 | 671 | 0.03 | Why? |
| Logistic Models | 2 | 2021 | 9089 | 0.03 | Why? |
| Influenza A Virus, H3N2 Subtype | 1 | 2018 | 572 | 0.03 | Why? |
| Risk Factors | 3 | 2018 | 71621 | 0.03 | Why? |
| Professional-Patient Relations | 1 | 2018 | 426 | 0.03 | Why? |
| Policy | 1 | 2021 | 1372 | 0.03 | Why? |
| Epidemiologic Methods | 1 | 2017 | 392 | 0.03 | Why? |
| Administration, Oral | 1 | 2020 | 2340 | 0.03 | Why? |
| Surge Capacity | 1 | 2021 | 894 | 0.03 | Why? |
| Shock | 1 | 2020 | 1868 | 0.03 | Why? |
| Benchmarking | 1 | 2017 | 627 | 0.03 | Why? |
| Drug Monitoring | 1 | 2021 | 1408 | 0.03 | Why? |
| Airway Extubation | 1 | 2018 | 403 | 0.03 | Why? |
| Mortality | 2 | 2021 | 7132 | 0.03 | Why? |
| Cardiologists | 1 | 2017 | 366 | 0.03 | Why? |
| New Zealand | 1 | 2019 | 2073 | 0.03 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2021 | 1731 | 0.03 | Why? |
| History, 20th Century | 1 | 2018 | 1282 | 0.03 | Why? |
| Drug Resistance, Viral | 1 | 2018 | 1083 | 0.03 | Why? |
| Hospital Mortality | 3 | 2021 | 22087 | 0.03 | Why? |
| Bayes Theorem | 1 | 2021 | 3237 | 0.03 | Why? |
| Visual Acuity | 1 | 2018 | 790 | 0.03 | Why? |
| Workflow | 1 | 2021 | 2373 | 0.03 | Why? |
| History, 21st Century | 1 | 2018 | 1849 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2020 | 4260 | 0.03 | Why? |
| Patient Preference | 1 | 2018 | 750 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.03 | Why? |
| Plasma | 1 | 2020 | 1809 | 0.02 | Why? |
| Propensity Score | 1 | 2018 | 2690 | 0.02 | Why? |
| Odds Ratio | 1 | 2021 | 5861 | 0.02 | Why? |
| Antiparkinson Agents | 1 | 2010 | 125 | 0.02 | Why? |
| Neoplasms | 1 | 2018 | 17251 | 0.02 | Why? |
| Disease Outbreaks | 1 | 2017 | 27595 | 0.02 | Why? |
| Health Facilities | 1 | 2017 | 1230 | 0.02 | Why? |
| Dexamethasone | 1 | 2020 | 2055 | 0.02 | Why? |
| Pain Management | 1 | 2017 | 854 | 0.02 | Why? |
| Markov Chains | 1 | 2010 | 502 | 0.02 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 8811 | 0.02 | Why? |
| Disaster Planning | 1 | 2021 | 1680 | 0.02 | Why? |
| Cost of Illness | 1 | 2018 | 1903 | 0.02 | Why? |
| International Cooperation | 1 | 2021 | 3436 | 0.02 | Why? |
| Risk Assessment | 1 | 2011 | 25439 | 0.02 | Why? |
| Poverty | 1 | 2018 | 2302 | 0.02 | Why? |
| Qualitative Research | 1 | 2018 | 4337 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Australia | 1 | 2019 | 6306 | 0.02 | Why? |
| Risk | 1 | 2018 | 5288 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2018 | 51949 | 0.02 | Why? |
| Seasons | 1 | 2018 | 4071 | 0.02 | Why? |
| Cognition Disorders | 1 | 2010 | 574 | 0.02 | Why? |
| Immunologic Factors | 1 | 2021 | 4206 | 0.02 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.02 | Why? |
| Time-to-Treatment | 1 | 2020 | 5883 | 0.02 | Why? |
| Developing Countries | 1 | 2018 | 4283 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Nurses | 1 | 2017 | 2285 | 0.01 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.01 | Why? |
| Sepsis | 1 | 2018 | 3517 | 0.01 | Why? |
| Patient Admission | 1 | 2018 | 5250 | 0.01 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 3832 | 0.01 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.01 | Why? |
| Communication | 1 | 2018 | 5206 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.01 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.01 | Why? |
| Infant, Newborn | 1 | 2018 | 23105 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| Infant | 1 | 2018 | 30274 | 0.01 | Why? |
| Biomarkers | 1 | 2018 | 23361 | 0.01 | Why? |
| Child, Preschool | 1 | 2018 | 36283 | 0.01 | Why? |
| Telemedicine | 1 | 2021 | 25032 | 0.01 | Why? |
| Quality of Life | 1 | 2010 | 9820 | 0.01 | Why? |